Candel Therapeutics appoints Martine Zimmermann to board of directors
CADL•Zimmermann's background
Zimmermann is executive vice president and head of Regulatory Affairs, Quality and Alliance Management at Inventiva.
She previously led global regulatory affairs and R&D quality at Ipsen Biopharmaceuticals and held senior regulatory leadership roles at Alexion Pharma International.
Board appointment adds regulatory expertise
Candel Therapeutics said Martine Zimmermann joined its board of directors effective Sept. 8, 2026.
The company said the appointment adds regulatory and quality expertise as it targets a fourth-quarter 2026 BLA filing for aglatimagene besadenovec.
